Message From the Editor-in-Chief
Message From the Editor-in-Chief ― Circulation Reports: 4 Years of Progress After Launch ―
2023 Volume 5 Issue 1 Pages 1-3
Details
2023 Volume 5 Issue 1 Pages 1-3
Dear Colleagues,
Welcome to the first issue of Circulation Reports (Circ Rep) in 2023. On January 10, 2019, Circ Rep, a sister journal to Circulation Journal, was launched as an official journal of the Japanese Circulation Society. During the past 4 years, we have had great success by publishing many interesting papers not only from Japan, but also from all over the world. On March 12, 2021, all papers published in Circ Rep became searchable in PubMed Central®. The editorial team are doing everything they can to obtain an impact factor for Circ Rep as soon as possible.
Here, I would like to take the opportunity to summarize the progress of Circ Rep over the first 4 years.
Figure 1 shows the number of manuscripts submitted to the Journal. We receive approximately 10–20 manuscripts each month. In 2021, when all Circ Rep papers became searchable in PubMed Central®, the number of submissions increased. As of November 11, 2022, 552 manuscripts had been submitted: 60.1% were de novo submissions and 39.9% manuscripts were transferred from Circulation Journal. Figure 2 shows the types of manuscripts submitted. Major categories are Clinical Investigation and Images in Cardiovascular Medicine, although some manuscripts are classified as a Statement/Opinion or Protocol Paper, which are categories unique to this Journal. Figure 3 shows the countries from which countries manuscripts have been submitted. Although most submissions are from Japan, we have received 24 manuscripts from the US.
The number of manuscripts submitted each month to Circulation Reports from October 2018 to July 2022.
Types of manuscripts submitted to Circulation Reports.
Countries from which manuscripts were submitted to Circulation Reports.
The acceptance rate in Circ Rep is 80.2%. Most manuscripts transferred from Circulation Journal have been accepted without delay after the Editor-in-Chief has carefully checked the revised manuscripts and the authors’ replies to the original reviewers. In 2022, the average time from submission to acceptance was 32.6 days. The average time from acceptance to advance online publication was 25.6 days. The editorial team continues to make efforts to minimize the time from submission to publication.
In 2019, 2020, 2021 and 2022, Circ Rep published 109, 118, 124, and 94 excellent papers, respectively. The top 10 papers most frequently viewed are listed in the Table.
| Rank | Access* | Paper |
|---|---|---|
| 1 | 2,695 | Hori K, Usuba K, Sakuyama A, Adachi Y, Hirakawa K, Nakayama A, et al. Hospitalization-associated disability after cardiac surgery in elderly patients: Exploring the risk factors using machine learning algorithms. Circ Rep 2021; 3: 423–430, doi:10.1253/circrep.CR-21-0057. |
| 2 | 2,408 | Nakai M, Iwanaga Y, Sumita Y, Kanaoka K, Kawakami R, Ishii M, et al; on the behalf of the JROAD Investigators. Validation of acute myocardial infarction and heart failure diagnoses in hospitalized patients with the nationwide claim-based JROAD-DPC database. Circ Rep 2021; 3: 131–136, doi:10.1253/circrep.CR-21-0004. |
| 3 | 1,937 | Ueda T, Kasama S, Yamamoto M, Nakano T, Ueshima K, Morikawa Y, et al; CANONICAL Study Group. Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes. Circ Rep 2021; 3: 440–448, doi:10.1253/circrep.CR-21-0030. |
| 4 | 1,883 | Kanaoka K, Soeda T, Terasaki S, Nishioka Y, Myojin T, Kubo S, et al. Current status and effect of outpatient cardiac rehabilitation after percutaneous coronary intervention in Japan. Circ Rep 2021; 3: 122–130, doi:10.1253/circrep. CR-20-0143. |
| 5 | 1,860 | Yoshida N, Iwata S, Ogawa M, Izawa KP, Kuroda S, Kohsaka S, et al. Intensive care unit admission for moderate- to-severe COVID-19 patients with known cardiovascular diseases or their risk factors: Insights from a nationwide Japanese cohort study. Circ Rep 2021; 3: 375–380, doi:10.1253/circrep.CR-21-0066. |
| 6 | 1,776 | Kida K, Nishitani-Yokoyama M, Oishi S, Kono Y, Kamiya K, Kishi T, et al; for the Japanese Association of Cardiac Rehabilitation (JACR) Public Relations Committee. Nationwide survey of Japanese cardiac rehabilitation training facilities during the coronavirus disease 2019 outbreak. Circ Rep 2021; 3: 311–315, doi:10.1253/circrep.CR-21-0042. |
| 7 | 1,654 | Okuyama M, Jiang W, Yang L, Subramanian V. Mst1/2 kinases inhibitor, XMU-MP-1, attenuates angiotensin II-induced ascending aortic expansion in hypercholesterolemic mice. Circ Rep 2021; 3: 259–266, doi:10.1253/ circrep.CR-20-0104. |
| 8 | 1,637 | Abrantes AM, Nogueira-Garcia B, Alves M, Passos DT, Brito D, Pinto FJ, et al. Low-dose colchicine in coronary artery disease: Systematic review and meta-analysis. Circ Rep 2021; 3: 457–464, doi:10.1253/circrep.CR-21-0065. |
| 9 | 1,586 | Mizuno A, Matsumoto C, Yoneoka D, Kishi T, Ishida M, Sanada S, et al. Cardiology Department practices in the first wave of the coronavirus disease pandemic: A nationwide survey in Japan by the Japanese Circulation Society. Circ Rep 2021; 3: 137–141, doi:10.1253/circrep.CR-21-0002. |
| 10 | 1,533 | Senoo K, Miki T, Okura T, Shiraishi H, Shirayama T, Inoue K, et al. Diagnostic value of atrial fibrillation by built-in electrocardiogram technology in a blood pressure monitor. Circ Rep 2020; 2: 345–350, doi:10.1253/circrep. CR-20-0032. |
*The number of times the online journal bibliographic information has been viewed over the past 2 years.
Once again, I would like to emphasize that the editorial team is doing its best every day to get an impact factor for Circ Rep. Finally, I acknowledge all associate editors and reviewers for their excellent, quick work and commitment to reviewing the manuscripts. I also thank the secretaries in the editorial office for their continuous support. I hope that more and more manuscripts will be submitted to Circ Rep from all over the world this year.
